evolocumab

all catalysts(0)

nothing on the calendar yet

News(10)

• New data could widen use of AstraZeneca, Amgen immune disease drug
  Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.
  biopharma_dive · 1mo ago
• Scribe’s early-stage IPO standout defies biotech’s derisking trend
  Scribe Therapeutics’ one-time epigenetic treatment is designed to slash the adherence burden of chronic cholesterol-lowering therapies while sidestepping the irreversibility of gene editing.
  biospace · 1mo ago
• AstraZeneca scores in lung cancer; Sandoz inks a China deal
  A combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism drug.
  biopharma_dive · 1mo ago
• Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars
  The initial batch of biosimilars includes copies of Amgen, Eli Lilly and GSK drugs that collectively generate billions of dollars in annual revenues.
  biospace · 1mo ago
• Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
  The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.
  biopharma_dive · 1mo ago
• Amgen’s MariTide stands alone after obesity cull while analysts seek more M&A
  Amgen has discontinued Phase 1 obesity candidate AMG 513, leaving MariTide as its sole weight loss asset. Meanwhile, executives said the company’s late-stage pipeline is largely full and future bus…
  biospace · 2mo ago
• Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
  In vivo gene editing outfit Scribe Therapeutics has priced its IPO at $128.7 million, surpassing the $96 million goal set out earlier this week.
  fiercebiotech · 2mo ago
• Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds
  Scribe Therapeutics has put its IPO plans down on paper, showing the genetic medicine company hopes to raise $96 million through its public listing.
  fiercebiotech · 2mo ago
• Merck wins first approval of a PCSK9 cholesterol pill
  The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former FDA commissioner Marty Makary.
  biopharma_dive · 2mo ago
• Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitor
  Merck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options.
  biospace · 2mo ago